Uterus Malignancies /5/15

Similar documents
NAACCR Webinar Series /7/17

Staging and Treatment Update for Gynecologic Malignancies

Uterine Malignancies. Collecting Cancer Data: Uterine Malignancies 10/7/2010. NAACCR Webinar Series 1. Questions. Fabulous Prizes!!!

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

C ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)

Endometrial Cancer. Incidence. Types 3/25/2019

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Jacqui Morgan March 6, 2019

CPC on Cervical Pathology

Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE

Cervical Cancer: 2018 FIGO Staging

NAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary

Type I. Type II. Excess estrogen Lynch Endometrioid adenocarcinoma PTEN. High grade More aggressive Serous, Clear Cell p53

ARROCase: Locally Advanced Endometrial Cancer

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Cervical cancer presentation

CARCINOMA CERVIX. Dr. PREETHI REDDY. B. M S OBG II yr POST GRADUATE.

What is endometrial cancer?

The International Federation of Gynecology and Obstetrics (FIGO) updated the staging

Coversheet for Network Site Specific Group Agreed Documentation

UTERINE SARCOMA EXAMPLE OF A UTERINE SARCOMA USING PROPOSED TEMPLATE

Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

Invasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous

Endometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines

of surgical management of early invasive cervical cancer chapter Diagnosis and staging Wertheim described the principles

Case Scenario 1. History

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates

Janjira Petsuksiri, M.D

Cervical Cancer Early Detection, Diagnosis, and Staging

PORTEC-4. Patient seqnr. Age at inclusion (years) Hospital:

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

This protocol is intended to assist pathologists in providing

Testicular Malignancies /8/15

Algorithms for management of Cervical cancer

Gynecologic Cancers. What is Gynecologic Cancer. Who is at risk for GYN cancer? 3/1/2018 1

Adjuvant Therapies in Endometrial Cancer. Emma Hudson

Guidelines for Assigning Summary Stage 2000

ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป

Role and Techniques of Surgery in Carcinoma Cervix. Dr Vanita Jain Additional Professor OBGYN PGIMER, Chandigarh

Vaginal intraepithelial neoplasia

Carcinoma of the Urinary Bladder Histopathology

Ritu Salani, M.D., M.B.A. Assistant Professor, Dept. of Obstetrics & Gynecology Division of Gynecologic Oncology The Ohio State University

Quiz. b. 4 High grade c. 9 Unknown

2009 USCAP Gyn Pathology Evening Session Case #3. Richard J. Zaino, MD Hershey Medical Center Penn State University Hershey, PA

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

ARRO Case: Early-stage Endometrial Cancer

Vulvar Carcinoma. Definition: Cases should be classified as carsinoma of the vulva when the primary site growth is in the vulva Malignant melanoma sho

ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)

Histology Coding ANSWERS

Endometrium. Protocol applies to all carcinomas of the endometrium. Procedures Cytology (No Accompanying Checklist) Biopsy Curettage Hysterectomy

Most common cancer Africans & Asians more prone because of poor socioeconomic condition Drastic decline in west as more detection of preinvasive

The new FIGO classification in endometrial carcinoma

Anatomy of the Female Reproductive System. Overview of Major GYN Cancer Characteristics. Multiple Primary and Histology Coding Rules

Estimated New Cancers Cases 2003

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR

UICC TNM 8 th Edition Errata

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

UICC TNM 8 th Edition Errata

Gynaecology NSSG (Lancs & South Cumbria) Uterine Cancer Guidelines (V4.0)

GYN Malignancies. Anatomy of the Female Reproductive System. Overview of Major GYN Cancer Characteristics. Multiple Primary and Histology Coding Rules

Anatomy of the Female Reproductive System. Overview of Major GYN Cancer Characteristics. Multiple Primary and Histology Coding Rules

Gynecologic Oncology Overview Staging updates and Soap Box Issues

Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report?

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank

UICC 8 th Edition Errata 25 th of May 2018

Current staging of endometrial carcinoma with MR imaging

Case Scenario 1. 1/2/13 History: 64-year-old white female presented with right leg swelling and redness, abdominal pain.

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.

Gynecologic Malignancies. Kristen D Starbuck 4/20/18

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Vaginal Cancer Early Detection, Diagnosis, and Staging

Chapter 8 Adenocarcinoma

Interactive Staging Bee

MRI in Cervix and Endometrial Cancer

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

ENDOMETRIAL CANCER: A GUIDE FOR PATIENTS

Imaging of endometrial and cervical cancer

Guideline for the Management of Vulval Cancer

Q&A. Collecting Cancer Data: Bladder. Collecting Cancer Data: Bladder 3/3/2011. NAACCR Webinar Series 1. Agenda

Cervical cancer is a disease in which malignant (cancer) cells form in the tissues of the cervix.

Case 1. Gynaecology Case Presentation. Objectives. Disclosures 22/10/ year old female Clinical history: Assess right ovarian cyst

MANAGEMENT OF CERVICAL CANCER

Gastric Cancer Histopathology Reporting Proforma

Referral and Management Guidelines for Gynaecological Cancers within North Trent

ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data

Carcinoma of the Cervix Histopathology Reporting Guide

COLLECTING CANCER DATA: STOMACH AND ESOPHAGUS

Gynecological Cancers in Primary Care

VULVAR CARCINOMA. Page 1 of 5

Transcription:

Collecting Cancer Data: Uterus 2014-2015 NAACCR Webinar Series February 5, 2015 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar at your site, please collect their names and emails. We will be distributing a Q&A document in about one week. This document will fully answer questions asked during the webinar and will contain any corrections that we may discover after the webinar. 2 FABULOUS PRIZES 3 Series 1

OVERVIEW KEY FACTS-PROJECTIONS Uterine Cervix New cases: 12,900 Deaths: 4,100 Uterine Corpus New cases: 54,870 Deaths: 10,170 Cancer Facts & Figures 2015 HUMAN PAPILLOMA VIRUS (HPV) INFECTION Epidemiologic studies convincingly demonstrate that the major risk factor for development of preinvasive or invasive carcinoma of the cervix is HPV infection About two-thirds of all cervical cancers are caused by HPV 16 and 18 Infection with HPV is common Pap tests look for changes in cervical cell caused by HPV infection Series 2

ANATOMY 7 LAYERS OF THE UTERUS Endometrium Functional Basal Myometrium Parametrium The loose connective tissue around the uterus. Perimetrium Peritoneum covering of the fundus and ventral and dorsal aspects of the uterus Series 3

FEMALE PELVIS CERVIX Ectocervix External os Endocervix Internal os CARCINOMA IN SITU OF THE CERVIX, CIN, AND THE BETHESDA SYSTEM In 1993 a NAACCR multidisciplinary group recommended that until There is a strong local interest Sufficient resources are available to collect all high grade squamous intraepithelial lesions That population based registries discontinue collection NAACCR and NPCR adopted this recommendation at that time. SEER and CoC adopted it effective for 1/1/1996. Series 4

HISTOLOGY-CERVIX Columnar Epithelium Adenocarcinoma Squamous Epithelium Squamous cell carcinoma Squamo-columnar junction Original New CERVICAL ECTROPION The central (endocervical) columnar epithelium protrudes out through the external os of the cervix and onto the vaginal portion of the cervix Undergoes squamous metaplasia, and transforms to stratified squamous epithelium. HISTOLOGY- ENDOMETRIUM Adenocarcinoma of the endometrium Type 1 Endometrioid adenocarcinoma grades 1&2 75-80% Type 2 Endometriod adenocarcinoma grade 3 Papillary serous carcinoma 10% Clear cell carcinoma 4% Mucinous carcinoma 1% Mixed 10% Series 5

MP/H RULES-TABLE 2 OTHER SITES Required Histology Combined Histology Gyn malignancies Clear Cell with two or more of Endometrioid the histologies in Mucinous column 2 Papillary Serous Squamous Transitional Combination Term Mixed cell adenocarcinoma Code 8323/3 EXAMPLE A single tumor of the endometrium: Endometrioid with clear cell differentiation. Rule H16 refers us to Table 2 Mixed cell adenocarcinoma 8323/3 Slide Changed HISTOLOGY Carcinosarcoma (CS Schema Corpus Carcinoma) Mixed Mullerian Leiomyosarcoma (CS Schema Corpus Sarcoma) Rhabdomyosarcoma Endometrial stromal sarcoma (CS Corpus Schema Sarcoma) Adenosarcoma (CS Schema Corpus Adenosarcoma) Series 6

Cervix Uteri M1 Corpus Uteri N2 N1 Sacral/ Parasacral Para-aortic Common Iliac External Iliac Internal Iliac http://visualsonline.cancer.gov/details.cfm?imageid=1770 19 DISTANT METASTASIS Cervix Para-aortic lymph nodes Mediastinal lymph nodes Lung Peritoneal Skeleton DISTANT METASTASIS Endometrium Intra abdominal metastasis Peritoneal surfaces Omentum Distant Lung Distant lymph nodes Series 7

STAGING: UTERUS 22 AJCC Cancer Stage CERVIX UTERI: CHAPTER 35 23 AJCC CANCER STAGE: CERVIX UTERI ICD-O-3 Topography Codes C53.0, C53.1, C53.8, C53.9 ICD-O-3 Histology Code Ranges 8000-8576 8940-8950 8980-8981 24 Series 8

AJCC CANCER STAGE: CERVIX UTERI CLASSIFICATION Clinical Staging FIGO uses clinical staging Determined prior to start of definitive therapy Clinical examination Palpation, inspection, colposcopy, endocervical curettage, hysteroscopy, cystoscopy, proctoscopy, intravenous urography, and x-ray of lungs and skeleton Lymph node status Radiologic-guided fine needle aspiration, laparoscopic or peritoneal biopsy, or lymphadenectomy 25 AJCC CANCER STAGE: CERVIX UTERI CLASSIFICATION Clinical Staging CT, MRI, PET Ignore for staging May be used to make treatment plan 26 AJCC CANCER STAGE: CERVIX UTERI CLASSIFICATION Pathologic Staging Based on information acquired before treatment and supplemented by additional evidence from surgery, particularly from pathologic exam of resected tissues Does not change clinical staging 27 Series 9

AJCC CANCER STAGE: CERVIX UTERI T CATEGORY TNM FIGO TX T0 Tis Description Primary tumor cannot be assessed No evidence of primary tumor Carcinoma in situ 28 AJCC CANCER STAGE: CERVIX UTERI T CATEGORY TNM FIGO Description T1 I Confined to uterus (extension to corpus should be disregarded) T1a IA Invasive carcinoma diagnosed only by microscopy; maximum depth of stromal invasion 5 mm & horizontal spread 7 mm or less T1a1 IA1 Stromal invasion 3 mm or less in depth & 7 mm or less horizontal spread T1a2 IA2 Stromal invasion more than 3 mm & not more than 5 mm with 7 mm or less horizontal spread 29 AJCC CANCER STAGE: CERVIX UTERI T CATEGORY TNM FIGO Description T1 I Confined to uterus (extension to corpus should be disregarded) T1b IB Clinically visible lesion confined to cervix or microscopic lesion greater than T1a/IA2 T1b1 IB1 Clinically visible lesion 4 cm or less in greatest dimension T1b2 IB2 Clinically visible lesion more than 4 cm in greatest dimension 30 Series 10

AJCC CANCER STAGE: CERVIX UTERI T CATEGORY TNM FIGO Description T2 II Invades beyond uterus but not to pelvic wall or lower third of vagina T2a IIA Without parametrial invasion T2a1 IIA1 Clinically visible lesion 4 cm or less in greatest dimension T2a2 IIA2 Clinically visible lesion more than 4 cm in greatest dimension T2b IIB Tumor with parametrial invasion 31 AJCC CANCER STAGE: CERVIX UTERI T CATEGORY TNM FIGO Description T3 III Extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or nonfunctioning kidney T3a IIIA Involves lower third of vagina, no extension to pelvic wall T3b IIIB Extends to pelvic wall and/or causes hydronephrosis or non-functioning kidney T4 IVA Invades mucosa of bladder or rectum and/or extends beyond true pelvis 32 AJCC CANCER STAGE: CERVIX UTERI N CATEGORY TNM FIGO Description NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 IIIB Regional lymph node metastasis 33 Series 11

AJCC CANCER STAGE: CERVIX UTERI M CATEGORY TNM FIGO Description M0 No distant metastasis M1 IVB Distant metastasis 34 AJCC CANCER STAGE: CERVIX UTERI Group T N M Stage 0 Tis N0 M0 Stage I T1 N0 M0 Stage IA T1a N0 M0 Stage IA1 T1a1 N0 M0 Stage IA2 T1a2 N0 M0 Stage IB T1b N0 M0 Stage IB1 T1b1 N0 M0 Stage IB2 T1b2 N0 M0 35 AJCC CANCER STAGE: CERVIX UTERI Group T N M Stage II T2 N0 M0 Stage IIA T2a N0 M0 Stage IIA1 T2a1 N0 M0 Stage IIA2 T2a2 N0 M0 Stage IIB T2b N0 M0 36 Series 12

AJCC CANCER STAGE: CERVIX UTERI Group T N M Stage III T3 N0 M0 Stage IIIA T3a N0 M0 Stage IIIB T3b T1-3 Any N N1 M0 M0 Stage IVA T4 Any N M0 Stage IVB Any T Any N M1 37 POP QUIZ Clinical exam & colposcopy: Visible lesion of cervix, 2.5 cm; no lymphadenopathy. Chest x-ray: Normal. Curettage and cervical biopsy: Moderately differentiated squamous cell carcinoma of cervix with 1.5 mm depth of stromal invasion. Radical hysterectomy operative report: 2.5cm cervical tumor confined to cervix. Pathology report: 2.3 cm moderately differentiated squamous cell carcinoma with a depth of invasion of 6.0 mm. 38 POP QUIZ What is the AJCC clinical stage? What is the AJCC pathologic stage 39 Series 13

Summary Stage 2000 http://seer.cancer.gov/tools/ssm/ CERVIX UTERI 40 SUMMARY STAGE 2000: CERVIX UTERI 0 In situ Noninvasive; intraepithelial Preinvasive Cancer in situ WITH endocervical gland involvement CIN (cervical intraepithelial neoplasia) grade III 41 SUMMARY STAGE 2000: CERVIX UTERI 1 Localized only Invasive cancer confined to cervix uteri Minimal microscopic stromal invasion < 3 mm in depth and < 7 mm in horizontal spread FIGO Stage IA1 Microinvasion; Tumor WITH invasive component > 3 mm and < 5 mm in depth, taken from the base of the epithelium, and < 7 mm in horizontal spread FIGO Stage IA2 42 Series 14

SUMMARY STAGE 2000: CERVIX UTERI 1 Localized only Invasive cancer confined to cervix uteri Invasive cancer confined to cervix and tumor > 5 mm in depth and/or > 7 mm in horizontal spread FIGO Stage IB FIGO Stage I not further specified Localized NOS: Confined to cervix uteri Confined to uterus NOS (except corpus uteri NOS) 43 SUMMARY STAGE 2000: CERVIX UTERI 2 Regional by direct extension only Extension to/involvement of: Corpus uteri, cul de sac (rectouterine pouch), upper 2/3 of vagina including fornices, vagina NOS, vaginal wall NOS FIGO Stage IIA Extension to: Ligament(s): Broad, cardinal, uterosacral Parametrium (paracervical soft tissue) FIGO Stage IIB 44 SUMMARY STAGE 2000: CERVIX UTERI 2 Regional by direct extension only Extension to: Bladder NOS excluding mucosa, bladder wall, lower 1/3 of vagina, rectal wall NOS, rectum NOS excluding mucosa, ureter intra- and extramural, vulva Bullous edema of bladder mucosa FIGO Stage IIIA 45 Series 15

SUMMARY STAGE 2000: CERVIX UTERI 2 Regional by direct extension only Extension to: Fallopian tube(s), ovary(ies), pelvic wall(s), urethra FIGO Stage IIIB Tumor causes hydronephrosis or nonfunctioning kidney FIGO Stage IIIB FIGO Stage III NOS 46 SUMMARY STAGE 2000: CERVIX UTERI 3 Regional lymph node(s) involved only Iliac NOS: Common; external; internal (hypogastric) NOS obturator Paracervical Parametrial Pelvic NOS Sacral NOS: Lateral (laterosacral); middle (promontorial) (Gerota s node); presacral; uterosacral Regional lymph node(s) NOS 47 SUMMARY STAGE 2000: CERVIX UTERI 4 Regional by BOTH direct extension AND regional lymph node(s) involved Codes (2) + (3) 5 Regional NOS FIGO Stage III NOS 48 Series 16

SUMMARY STAGE 2000: CERVIX UTERI 7 Distant site(s)/node(s) involved Distant lymph node(s): Aortic, NOS: Lateral (lumbar), para-aortic, periaortic Inguinal Mediastinal Other distant lymph node(s) Extension to: Bladder mucosa (excluding bullous edema); rectal mucosa Further contiguous extension beyond true pelvis: Sigmoid colon; small intestine Metastasis FIGO Stage IV, IVA, IVB 49 POP QUIZ Clinical exam & colposcopy: Visible lesion of cervix, 2.5 cm; no lymphadenopathy. Chest x-ray: Normal. Curettage and cervical biopsy: Moderately differentiated squamous cell carcinoma of cervix with 1.5 mm depth of stromal invasion. Radical hysterectomy operative report: 2.5cm cervical tumor confined to cervix. Pathology report: 2.3 cm cervical lesion, moderately differentiated squamous cell carcinoma, with a depth of invasion of 6.0 mm. 50 POP QUIZ What is the code for Summary Stage 2000? a. 0 In situ b. 1 Localized only c. 2 Regional by direct extension only d. 3 Regional lymph node(s) involved only e. 4 Regional by BOTH direct extension AND regional lymph node(s) involved f. 5 Regional NOS g. 7 Distant site(s)/node(s) involved h. 9 Unknown if extension or metastasis 51 Series 17

Collaborative Stage Data Collection System (CS) V0205 CERVIX UTERI 52 CS: CERVIX UTERI CS Tumor Size Code the largest measurement of horizontal spread or surface diameter CS Extension T category is based on CS Tumor Size for CS Extension codes 200-310, 380-450, and 550 ONLY Derives T1b1, T1b2, T1bNOS, T1NOS, T2a1, T2a2, T2aNOS, T2NOS 53 SSF1: CERVIX UTERI FIGO stage Code as documented in medical record Do not try to code from T, N, M values Assign code 987 for carcinoma in situ or CIN III CS Extension = 000 or 010 FIGO Stage does not include Stage 0 (in situ) for cervix uteri Assign code 999 if FIGO stage is unknown or not documented Series 18

CORPUS UTERI: CHAPTER 36 55 AJCC CANCER STAGE: CORPUS UTERI ICD-O-3 Topography Codes C54.0, C54.1, C54.2, C54.3, C54.8, C54.9, C55.9 ICD-O-3 Histology Code Ranges 8000-8576 8890-8898 8930-8933 8940-8950 8980-8981 56 AJCC CANCER STAGE: CORPUS UTERI 2 separate staging schemas Uterine carcinomas Includes carcinosarcoma Uterine sarcomas Leiomyosarcoma & endometrial stromal sarcoma Adenosarcoma 57 Series 19

AJCC CANCER STAGE: CORPUS UTERI CLASSIFICATION Clinical Staging Based on evidence acquired before initiation of treatment Pathologic Staging FIGO uses surgical/pathologic staging Based on information acquired before treatment supplemented by information acquired from pathologic assessment of resected tissues Record depth of myometrial invasion with thickness of myometrium Assess regional lymph nodes surgically/pathologically 58 T CATEGORY UTERINE CARCINOMA TNM FIGO Description TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis Carcinoma in situ T1 I Confined to corpus uteri T1a IA Limited to endometrium or invades less than ½ of myometrium T1b IB Invades ½ or more of myometrium 59 T CATEGORY UTERINE CARCINOMA TNM FIGO Description T2 II Invades stromal connective tissue of cervix but does not extend beyond uterus T3a IIIA Involves serosa and or adnexa (direct extension or metastasis) T3b IIIB Involves vagina (direct extension or metastasis) or parametrium T4 IV Invades bladder mucosa and/or bowel mucosa 60 Series 20

N CATEGORY UTERINE CARCINOMA TNM FIGO Description NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 IIIC1 Regional lymph node metastasis to pelvic nodes N2 IIIC2 Regional lymph node metastasis to para-aortic nodes with or without positive pelvic nodes 61 M CATEGORY UTERINE CARCINOMA TNM FIGO Description M0 No distant metastasis M1 IVB Distant metastasis 62 AJCC CANCER STAGE: CORPUS UTERI CARCINOMAS* Group T N M Stage 0 Tis N0 M0 Stage I T1 N0 M0 Stage IA T1a N0 M0 Stage IB T1b N0 M0 Stage II T2 N0 M0 *Carcinosarcoma should be staged as carcinoma. 63 Series 21

AJCC CANCER STAGE: CORPUS UTERI CARCINOMAS Group T N M Stage III T3 N0 M0 Stage IIIA T3a N0 M0 Stage IIIB T3b N0 M0 Stage IIIC1 T1-T3 N1 M0 Stage IIIC2 T1-T3 N2 M0 Stage IVA T4 Any N M0 Stage IVB Any T Any N M1 64 POP QUIZ Uterine biopsy: Endometrial adenocarcinoma CT scan pelvis/abdomen: Uterine mass, no lymphadenopathy, no organomegaly Hysterectomy, bilateral salpingooophorectomy, and pelvic node dissection: 3 cm endometrial adenocarcinoma, moderately differentiated, invading the pelvic sidewall; 0/6 pelvic nodes with metastasis; 0/6 para-aortic nodes with metastasis. 65 POP QUIZ What is the AJCC clinical stage? What is the AJCC pathologic stage? 66 Series 22

T CATEGORY LEIOMYOSARCOMA & ENDOMETRIAL STROMAL SARCOMA TNM FIGO Description TX Primary tumor cannot be assessed T0 No evidence of primary tumor T1 I Limited to uterus T1a IA Tumor 5 cm or less in greatest dimension T1b IB Tumor more than 5 cm 67 T CATEGORY LEIOMYOSARCOMA & ENDOMETRIAL STROMAL SARCOMA TNM FIGO Description T2 II Extends beyond the uterus within the pelvis T2a IIA Involves adnexa T2b IIB Involves other pelvic tissues T3 III Infiltrates abdominal tissues T3a IIIA One site T3b IIIB More than one site T4 IVA Invades bladder or rectum 68 N CATEGORY LEIOMYOSARCOMA & ENDOMETRIAL STROMAL SARCOMA TNM FIGO Description NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 IIIC Regional lymph node metastasis 69 Series 23

M CATEGORY LEIOMYOSARCOMA & ENDOMETRIAL STROMAL SARCOMA TNM FIGO Description M0 No distant metastasis M1 IVB Distant metastasis 70 POP QUIZ Uterine biopsy: Endometrial stromal sarcoma Abdominal/pelvic CT scan: Large uterine mass with no lymphadenopathy Chest x-ray: Normal Total hysterectomy with bilateral salpingooophorectomy: Enodmetrial stromal sarcoma of the myometrium involving left adnexa, left ovary, and omentum. 71 POP QUIZ What is the AJCC clinical stage? What is the AJCC pathologic stage? 72 Series 24

T CATEGORY ADENOSARCOMA TNM FIGO Description TX Primary tumor cannot be assessed T0 No evidence of primary tumor T1 I Limited to uterus T1a IA Limited to endometrium/endocervix T1b IB Invades less than ½ of myometrium T1c IC Invades more than ½ of myometrium 73 T CATEGORY ADENOSARCOMA TNM FIGO Description T2 II Extends beyond the uterus within the pelvis T2a IIA Involves adnexa T2b IIB Involves other pelvic tissues T3 III Involves abdominal tissues T3a IIIA One site T3b IIIB More than one site T4 IV Invades bladder or rectum 74 N CATEGORY ADENOSARCOMA TNM FIGO Description NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 IIIC Regional lymph node metastasis 75 Series 25

M CATEGORY ADENOSARCOMA TNM FIGO Description M0 No distant metastasis M1 IVB Distant metastasis 76 AJCC CANCER STAGE: CORPUS UTERI UTERINE SARCOMAS Group T N M Stage I T1 N0 M0 Stage IA T1a N0 M0 Stage IB T1b N0 M0 Stage IC T1c N0 M0 Stage II T2 N0 M0 77 AJCC CANCER STAGE: CORPUS UTERI UTERINE SARCOMAS Group T N M Stage IIIA T3a N0 M0 Stage IIIB T3b N0 M0 Stage IIIC T1, T2, T3 N1 M0 Stage IVA T4 Any N M0 Stage IVB Any T Any N M1 78 Series 26

Summary Stage 2000 http://seer.cancer.gov/tools/ssm/ CORPUS UTERI 79 SUMMARY STAGE 2000: CORPUS UTERI 0 In situ Noninvasive; intraepithelial Pre-invasive FIGO Stage 0 1 Localized only Confined to endometrium (stroma); FIGO Stage IA Invasion of myometrium/serosa of corpus (tunica serosa); FIGO Stage IB; FIGO Stage IC Localized NOS; FIGO Stage I not further specified 80 SUMMARY STAGE 2000: CORPUS UTERI Confined to endometrium In situ Tumor confined to columnar epithelium Localized Tumor penetrated basement membrane and invaded stroma (lamina propria) 81 Series 27

SUMMARY STAGE 2000: CORPUS UTERI 2 Regional by direct extension only Extension to/involvement of: Cervix uteri NOS; FIGO Stage II NOS Endocervical glandular involvement only; FIGO Stage IIA Cervical stromal invasion; FIGO Stage IIB Extension or metastasis within true pelvis: Fallopian tube(s); ligament(s): broad, round, uterosacral; ovary(ies); parametrium; pelvic serosa; pelvic tunica serosa; ureter; vulva 82 SUMMARY STAGE 2000: CORPUS UTERI 2 Regional by direct extension only Cancer cells in ascites Cancer cells in peritoneal washings FIGO Stage IIIA Extension or metastasis: Bladder NOS excluding mucosa; bladder wall; bowel wall NOS; rectum NOS excluding mucosa; vagina; pelvic walls FIGO Stage IIIB 83 SUMMARY STAGE 2000: CORPUS UTERI 3 Regional lymph node(s) involved only Aortic NOS: Lateral (lumbar), para-aortic, periaortic Iliac: Common, external, internal (hypogastric): obturator Paracervical Parametrial Pelvic NOS Sacral NOS: Lateral (laterosacral), middle (promontorial) (Gerota s node), presacral, uterosacral FIGO Stage IIIC Regional lymph node(s) NOS 84 Series 28

SUMMARY STAGE 2000: CORPUS UTERI 4 Regional by BOTH direct extension AND regional lymph node(s) involved Codes (2) + (3) 5 Regional NOS FIGO Stage III NOS 85 SUMMARY STAGE 2000: CORPUS UTERI 7 Distant site(s)/node(s) involved Distant lymph node(s): Inguinal NOS: Deep, NOS; Node of Cloquet or Rosenmuller (highest deep inguinal) Superficial inguinal (femoral) Other distant lymph node(s) 86 SUMMARY STAGE 2000: CORPUS UTERI 7 Distant site(s)/node(s) involved Extension to: Bladder mucosa (excluding bullous edema) Bowel mucosa FIGO Stage IVA Further contiguous extension: Abdominal serosa (peritoneum); cul de sac (rectouterine pouch); sigmoid colon; small intestine Metastasis FIGO Stage IVB 87 Series 29

POP QUIZ Uterine biopsy: Endometrial stromal sarcoma Abdominal/pelvic CT scan: Large uterine mass with no lymphadenopathy Chest x-ray: Normal Total hysterectomy with bilateral salpingooophorectomy: Enodmetrial stromal sarcoma of the myometrium involving left adnexa, left ovary, and omentum. 88 POP QUIZ What is the code for Summary Stage 2000? a. 0 In situ b. 1 Localized only c. 2 Regional by direct extension only d. 3 Regional lymph node(s) involved only e. 4 Regional by BOTH direct extension AND regional lymph node(s) involved f. 5 Regional NOS g. 7 Distant site(s)/node(s) involved h. 9 Unknown if extension or metastasis 89 Collaborative Stage Data Collection System (CS) V0205 CORPUS UTERI 90 Series 30

CORPUS UTERI SCHEMAS CS V0205 CorpusAdenosarcoma* ICD-O-3 Histology Code: 8933 CorpusCarcinoma* ICD-O-3 Histology Code Ranges: 8000-8790, 8950, 8951, 8980-8981,9700-9701 CorpusSarcoma* ICD-O-3 Histology Code Ranges: 8800-8932,8934-8941,8959-8974, 8982-9136,9141-9582 *ICD-O-3 Topography Codes: C54.0, C54.1, C54.2, C54.3, C54.8, C54.9, C55.9 91 SSF1 FIGO STAGE Code as documented in medical record Do not try to code from T, N, M values Assign code 987 for carcinoma in situ CS Extension = 000 FIGO Stage does not include Stage 0 (in situ) for corpus uteri Assign code 999 if FIGO stage is unknown or not documented 92 SSF2 PERITONEAL CYTOLOGY Code results of cytology from peritoneal or pelvic washings Negative, positive, or suspicious cytology Exam performed on Ascites Saline solution flooded in the pelvic & peritoneal cavities 93 Series 31

NUMBER OF NODES POSITIVE & EXAMINED SSF3: Number of Positive Pelvic Nodes SSF4: Number of Examined Pelvic Nodes SSF5: Number of Positive Para-aortic Nodes SSF6: Number of Examined Para-aortic Nodes 94 DIAGNOSIS AND TREATMENT DIAGNOSTIC/STAGING PROCEDURES Cervix PAP Smear Not as effective with adenocarcinoma Biopsy Colposcopy Cone biopsy Imaging MRI CT PET-CT Series 32

DIAGNOSTIC/STAGING PROCEDURES Endometrium Endometrial biopsy Fractional dilation and curettage (D&C) Hysteroscopy Imaging CT MRI CA 125 TREATMENT-CERVIX IA1 Fertility sparing Cone biopsy with margins negative and negative LVSI Active Surveillance Cone biopsy with positive margins or positive LVSI Radical trachelectomy and pelvic lymph node dissection May also have para-aortic lymph node dissection Non-fertility sparing Negative LVSI-Simple hysterectomy Positive LVSI-modified radical hysterectomy with pelvic lymph node dissection TRACHELECTOMY Removes the cervix and the upper part of the vagina but not the body of the uterus Preserves fertility 99 Series 33

SURGERY CODES 20 Local tumor excision, NOS 26 Excisional biopsy, NOS 27 Cone biopsy 24 Cone biopsy WITH gross excision of lesion 29 Trachelectomy; removal of cervical stump; cervicectomy Any combination of 20, 24, 26, 27 or 29 WITH 21 Electrocautery 22 Cryosurgery 23 Laser ablation or excision 25 Dilatation and curettage; endocervical curettage (for in situ only) 28 Loop electrocautery excision procedure (LEEP) 100 TREATMENT CERVIX IA2 Fertility sparing Radical trachelectomy and pelvic lymph node dissection May also be done for Stage IB1 if tumor is less than 2cm Non-fertility sparing Radical hysterectomy and bilateral pelvic lymph node dissection with (or without) para-aortic lymph node sampling Pelvic Radiation with brachytherapy for medically inoperable patients or those that refuse surgery. 101 TREATMENT-CERVIX IB and IIA Non-fertility sparing IB1 and 2A1-Radical hysterectomy and bilateral pelvic lymph node dissections with (or without) para aortic lymph node sampling Definitive radiation and brachytherapy +/- concurrent cisplatin based chemotherapy IB2 and IIA2-Concurrent chemoradiation Definitive pelvic radiation Concurrent cisplatin based chemotherapy and brachytherapy 102 Series 34

SENTINEL LYMPH NODE MAPPING A dye with a radiotracer is injected around the lesion The first nodes the dye travels to are the sentinel lymph nodes 103 EXTERNAL BEAM RADIATION THERAPY (EBRT) The volume of EBRT should cover the gross disease, parametria, uterosacral ligaments, sufficient vaginal margin, presacral nodes, other nodal volumes at risk BRACHYTHERAPY Low dose rate (LDR) High dose rate (HDR) Series 35

TREATMENT-CERVIX Advanced disease-stage IIB through IVA Radiation, cisplatin based chemotherapy and brachytherapy Metastatic disease Chemotherapy and radiation 106 TREATMENT-ENDOMETRIUM Confined to the uterus Total hysterectomy (with or without lymph node dissection) Cervical involvement Radical hysterectomy Neoadjuvant radiation Extrauterine disease Hysterectomy and debulking EBRT plus or minus vaginal brachytherapy Chemotherapy TREATMENT-ENDOMETRIUM Total hysterectomy/bilateral salpingo-oopherectomy Pelvic lymph node dissection Para-aortic lymph node dissection To the level of the renal vessels Peritoneal lavage Series 36

SYSTEMIC THERAPY Chemotherapy Cisplatin/doxorubicin plus or minus paclitaxel Hormone therapy Continuous progestin base therapy for state IA patients Fertility sparing Patient must meet specific criteria Requires frequent monitoring Hysterectomy should be completed after childbearing is complete QUESTIONS? COMING UP Abstracting & Coding Boot Camp 3/5/15 Collecting Cancer Data: Stomach & Esophagus 4/2/15 111 Series 37

AND THE WINNERS ARE 112 CE CERTIFICATE QUIZ/SURVEY Phrase Link http://www.surveygizmo.com/s3/1986035/uterus-2015 113 Series 38